ArticleJournal of pharmacy & bioallied sciences2025
The Occurrence of Non-Alcoholic Fatty Liver Disease among Individuals with Diabetes Mellitus: A Comparative Study.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This research aimed to investigate the occurrence and trends of non-alcoholic fatty liver disease (NAFLD) in individuals diagnosed with type 2 diabetes mellitus. Material and Methods: During the course of the study, a total of 100 patients with a diagnosis of type 2 diabetes mellitus were enrolled by researchers, adhering to defined inclusion and exclusion criteria. The diagnosis of NAFLD was confirmed via ultrasonography, which revealed a bright liver appearance. Results: The ultrasonography analysis revealed that 50% of the patients were diagnosed with fatty liver, leading to their classification in group A. The remaining patients, who exhibited no signs of fatty liver, were assigned to Group B. Group A exhibited significantly higher levels of serum AST, serum ALT, and serum alkaline phosphatase in comparison to Group B. Group B showed an elevated Serum AST/ALT ratio when compared to group A. Conclusion: The rising rates of obesity are increasingly linked to a surge in conditions such as type 2 diabetes mellitus and non-alcoholic fatty liver disease, has rendered the management of these patients more complex than ever. Clinicians must recognize the extrahepatic manifestations associated with NAFLD, as early identification of T2DM is crucial for effectively managing these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.